Am J Psychiatry 156:169-180, February 1999
©Copyright 1999 American Psychiatric Association
Sympathoadrenal Hyperactivity and the Etiology of Neuroleptic Malignant Syndrome
Ronald J. Gurrera, M.D.
OBJECTIVE: The author's goal was to develop a pathophysiological model for neuroleptic malignant syndrome with greater explanatory power than the alternative hypotheses of hypothalamic dopamine antagonism (elevated set point) and direct myotoxicity (malignant hyperthermia variant). METHOD: Published clinical findings on neuroleptic malignant syndrome were integrated with data from human and animal studies of muscle physiology, thermoregulation, and autonomic nervous system function. RESULTS: The data show that the sympathetic nervous system's latent capacity for autonomous activity is expressed when tonic inhibitory inputs from higher central nervous system centers are disrupted. These tonic inhibitory inputs are relayed to preganglionic sympathetic neurons by way of dopaminergic hypothalamospinal tracts. The sympathetic nervous system mediates hypothalamic coordination of thermoregulatory activity and is a primary regulator of muscle tone and thermogenesis, augmenting both of these when stimulated. In addition, the sympathetic nervous system modulates all of the other end-organs that function abnormally in neuroleptic malignant syndrome. CONCLUSIONS: There is substantial evidence to support the hypothesis that dysregulated sympathetic nervous system hyperactivity is responsible for most, if not all, features of neuroleptic malignant syndrome. A predisposition to more extreme sympathetic nervous system activation and/or dysfunction in response to emotional or psychological stress may constitute a trait vulnerability for neuroleptic malignant syndrome, which, when coupled with state variables such as acute psychic distress or dopamine receptor antagonism, produces the clinical syndrome of neuroleptic malignant syndrome. This hypothesis provides a more comprehensive explanation for existing clinical data than do the current alternatives.
This article has been cited by other articles:
|
|
|
|
 
T. Lenhard, C. Grimm, and P. A. Ringleb
Renal salt wasting as part of dysautonomia in Guillain-Barre syndrome
J. Neurol. Neurosurg. Psychiatry,
August 22, 2010;
(2010)
jnnp.2009.192369v1.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Mann and A. Sobel
An agitated young man
BMJ,
March 31, 2010;
340(mar31_1):
c732 - c732.
[Full Text]
|
|
|
|
|
|
|
The Necessity of Considering Serotonin Toxicity as a Differential Diagnosis for NMS-Like Symptoms
Journal of Pharmacy Practice,
October 1, 2009;
22(5):
518 - 519.
[PDF]
|
|
|
|
|
|
|
C. Montaurier, B. Morio, S. Bannier, P. Derost, P. Arnaud, M. Brandolini-Bunlon, C. Giraudet, Y. Boirie, and F. Durif
Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation
Brain,
July 1, 2007;
130(7):
1808 - 1818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Strawn, P. E. Keck Jr., and S. N. Caroff
Neuroleptic Malignant Syndrome
Am J Psychiatry,
June 1, 2007;
164(6):
870 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lenhard, S. Kulkens, and S. Schwab
Cerebral Salt-Wasting Syndrome in a Patient With Neuroleptic Malignant Syndrome
Arch Neurol,
January 1, 2007;
64(1):
122 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stotz, D. Thummler, M. Schurch, J.-C. Renggli, A. Urwyler, and H. Pargger
Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication
Br. J. Anaesth.,
December 1, 2004;
93(6):
868 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ihara, N. Kohara, F. Urano, H. Ichinose, S. Takao, T. Nishida, H. Saiki, Y. Kawamoto, A. Ikeda, S. Takagi, et al.
Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient
Neurology,
October 8, 2002;
59(7):
1102 - 1104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Turner and N. Gainsborough
Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen
J Psychopharmacol,
January 1, 2001;
15(1):
61 - 63.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Adnet, P. Lestavel, and R. Krivosic-Horber
Neuroleptic malignant syndrome
Br. J. Anaesth.,
July 1, 2000;
85(1):
129 - 135.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. DUGGAL and S. H. NIZAMIE
Sympathoadrenal Hyperactivity and Neuroleptic Malignant Syndrome
Am J Psychiatry,
April 1, 2000;
157(4):
663 - 663.
[Full Text]
|
|
|
|
|
|
|
N. A. QURESHI and T. A. AL-HABEEB
Sympathoadrenal Hyperactivity and Neuroleptic Malignant Syndrome
Am J Psychiatry,
February 1, 2000;
157(2):
310- - 311.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
